|
|
|
|
||
Strong Buy
EDAP – an ISRG déjà vu?The current development in Europe of EDAP TMS S.A. (EDAP; http://www.edap-tms.com), the leader in treating prostate cancer by using the high-intensity focused ultrasound (HIFU) technology evokes a déjà vu, remembering the early days of ISRG. In Europe HIFU is no longer considered as an experimental procedure and the older Ablatherm device is already steadily replaced by the much more sophisticated FocalOne, while Ablatherm has just received FDA approval in November 2015. As an example the urology centers using HIFU in Germany are listed here: http://www.prostatakrebse.de/informationen/pdf/HIFU-Zentren Deutschland EDAP TMS GmbH.pdf Accordingly already more than half of the German centers have switched to FocalOne. Europe-wide meanwhile about 60 centers use FocalOne, some of them by sharing mobile units. Content and effect of the coming conference call will be more than just interesting. The EDAP Board sleeps since october 2015. It would be interesting and helpful to resuscitate it and in particular to share the views with the knowledgeable members of the ISRG board. pasta |
return to message board, top of board |